Search
Iomeprol
go.drugbank.com/drugs/DB11705ApprovedInvestigational[A265090,A265095] Iomeprol first appeared in the market in 1994 [A265095] and is currently used in various diagnostic processes involving x-ray imaging and computed tomography (CT) scans.[L52260]
Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-5-(N-METHYLGLYCOLAMIDO)ISOPHTHALAMIDE, 1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)METHYLAMINO)-2,4,6-TRIIODO-Human papillomavirus type 16 L1 capsid protein antigen
go.drugbank.com/drugs/DB10301ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.
Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANOHuman papillomavirus type 18 L1 capsid protein antigen
go.drugbank.com/drugs/DB10302ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 18 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.
Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANOImlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigational[L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway. … [A256828] In clinical trials, imlunestrant has been investigated as monotherapy and in combination with other drugs in breast cancer patients.[A256828]
Mepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalThe pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue … Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.
Products: NUCALA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML, Nucala 100mg/ml Solution for Injection in pre-filled pen (Autoinjector)Patisiran
go.drugbank.com/drugs/DB14582ApprovedPatisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220]. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.
Categories: Compounds used in a research, industrial, or household settingGlyceryl monostearate
go.drugbank.com/drugs/DB11250ApprovedIt is commonly used as an emulsifier in foods.
Mixtures: Mycellcare All in One SerumOuabain
go.drugbank.com/drugs/DB01092ApprovedIt is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.
Categories: Compounds used in a research, industrial, or household settingInfluenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15704ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FLUAD Injektionssuspension in einer Fertigspritze, Sandovac Injektionssuspension in einer FertigspritzeAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261]